Reduce administrative intervention drug price reform "break ice" Guangdong first

Source: on November 13, 2014, the Guangdong health and Family Planning Commission issued the notice on Soliciting Opinions on the modification of relevant measures for drug trading rules of medical institutions in Guangdong Province, which is intended to revise the six aspects of basic drug and non-basic drug trading measures, drug purchase and distribution, drug settlement, trade supervision and management and trading institution management of the province The notice will give full play to the decisive role of market mechanism in the allocation of drug resources and reduce the interference of administrative power This is also the direction of future drug price system reform Compared with most drugs, blood products and anesthetics are not subject to local bidding price If the drug price system is adjusted, these two types of enterprises can take the lead in benefiting For other drugs, it is suggested that the medical insurance department should be responsible for bidding On the premise that the total amount of medical insurance payment is determined, drug companies can freely price according to market supply and demand In this way, we can not only bypass the restrictions of local bidding price, but also avoid the soaring drug price after the liberalization The competent price department will fade out three institutions, i.e the collection institution, the market price calculation institution and the highest temporary retail price computer institution, which are proposed to adjust the market price data source in Guangdong according to the consultation At present, all three institutions belong to the price department of Guangdong Province In the future, the three administrative functions will be replaced by provincial health and Family Planning Commission, provincial drug trading institutions and medical institutions respectively The result of the adjustment is to urge the price authorities to fade out of the price setting system The specific modification rules are as follows: the data such as the bid winning price of the same drug in different provinces and the current purchase price in Guangdong are revised from the original "collected by the provincial price department together with the provincial health department" to "collected by the provincial health and family planning department"; The market entry price shall be revised from the original "formulated by the provincial price department together with the provincial health department" to "calculated by the provincial drug trading agency and reviewed by the provincial development and reform department together with the provincial health and family planning department, the provincial human resources and social security department"; The maximum temporary retail price shall be calculated by the original "provincial price authority" according to the prescribed difference rate, and the maximum temporary retail price of each transaction price shall be revised to the "medical institution" according to the transaction price of each transaction to calculate the temporary retail price of the transaction varieties Industry insiders believe that the draft diluted the role of price departments in the price setting system, and the original intention should be to follow the idea of streamlining administration and delegating power proposed by the State Council, reduce the administrative power interference of government departments, and play the decisive role of market mechanism in the allocation of drug resources Guangdong's adjustment of low-cost drug trading rules also cheered the market According to the draft, low-cost drugs will be revised from the original "bargain trading" to "direct online" That is to say, within the daily average cost standard of Western medicine ≤ 3 yuan and Chinese patent medicine ≤ 5 yuan, the manufacturer shall make its own quotation, the trading institution shall directly hang the network, and the medical institution shall make its own choice It is understood that Guangdong Provincial Development and Reform Commission has previously cancelled the highest retail price of low-cost drugs within the pricing range of provincial and national development and Reform Commission, and the prices of nearly 7000 varieties of low-cost drugs have been liberalized In addition, the drug trading cycle has changed from monthly bidding to quarterly bidding, which undoubtedly reduces the pressure on enterprises Blood products and anesthetics benefited first after media reports said that the national development and Reform Commission would first release the prices of blood products, national unified procurement of preventive immunity drugs and contraceptives, class I mental and narcotic drugs and patent drugs before the end of 2014 In addition, the drug price in the medical insurance catalog is planned to be changed to the payment standard of medical insurance formulated by relevant departments, and the actual price is determined by the market "From the perspective of investment, this policy is of great benefit to two types of enterprises First is the current supply of blood products enterprises, followed by narcotics enterprises These two types of enterprises will benefit significantly from the adjustment of drug price management system " Industry insiders told China Securities News that the NDRC's drug price reform idea is to open up the establishment of retail prices However, prescription drugs are the most important among drugs If prescription drugs are to be sold in hospitals, they must first go through the bidding of local basic drugs and non-basic drugs In other words, although the highest retail price has been released, the bidding price remains unchanged, which actually has no impact on the sales price of drugs at the hospital end According to the provisions of the national development and Reform Commission on drug price management, the maximum retail price of drugs can be divided into three types: government pricing, government guidance price and market regulation price The pricing power of drug retail price shall be exercised by the State price administration department and the provincial price administration department respectively, and their respective pricing Catalogues shall be formulated And the local bidding price needs the bidding department to set the market price, and then the pharmaceutical enterprises will bid within the price range, and the lower one will win the bid, which will lead to fierce competition "Only blood products and anesthetics can be directly sold in hospitals without local bidding If the state deregulates the maximum retail price of drugs, these two types of enterprises can set prices freely according to cost and market supply and demand, and these two types of enterprises will benefit from the adjustment of drug price system first " "The rigid market of blood products is clear, but the long-term high prospect of the industry has not brought high profits to enterprises, and the products fail to rely on the relationship between supply and demand for market-oriented pricing, which makes the companies in the industry very passive in front of the huge market," said the industry insiders In this context, the valuation of blood products enterprises has been under pressure for a long time, and the dynamic P / E ratio of Hualan biology [1.45% capital research report], Tiantan biology [- 2.52% capital research report] and Boya biology [- 1.42% capital research report] has been lower than 30 times for a long time At present, the products of domestic blood products enterprises are mainly divided into two categories: one is human serum albumin and intravenous immunoglobulin (IV-C), most of which are capable of production; the other is small products represented by coagulation factors Blood products are basically included in the list of base drugs and subject to the maximum retail price In the past two years, the national development and Reform Commission has twice raised the maximum retail price of some blood products, from 360 yuan to 378 yuan for 10G / bottle of human serum albumin, with an increase of 5% However, compared with the difficulty and cost of plasma source collection, the price increase is "rare" The original price of Jingbing 2.5g/bottle is 412 yuan, and now it is mentioned as 561 yuan, with a high price increase "The difficulty and cost of plasma collection are increasing year by year Most blood products enterprises provide nutrition subsidies between 200 yuan / person and 300 yuan / person to plasma donors, which is significantly higher than the level of 150 yuan / person before 2010." Although the cost pressure is increasing day by day, the sale price is still under control The price deregulation is expected to improve the profit level of the enterprise, a senior executive of Boya biology told China Securities News The key to linking up with the medical insurance system is that "the relevant departments intend to liberalize the prices of four kinds of drugs, such as blood products, first-class spirit and narcotic drugs, patent drugs, etc., which will have a profound impact on the whole medical market and promote some structural changes in the pharmaceutical industry." Liao Xinbo, an inspector of the health and Family Planning Commission of Guangdong Province, said that although drug prices may rise due to the deregulation of drug prices, after the deregulation, the prices will tend to be reasonable, which can ensure the supply of drugs, and there will be no shortage of medicine This is in line with the law of the market, which can reduce the phenomenon of blindly lowering the drug price through administrative means in the past and make the drug price return to the right way An official from the drug administration of the national health and Family Planning Commission told China Securities News that the drug price deregulation looks beautiful, but it is far from expected to be so easy and fast "After the development and Reform Commission released the management of the highest retail price, how to link up with the medical insurance reimbursement system and the bidding system of the health sector is a major problem." Paying for health care is the difficulty, the officials said The supporting system of drug free pricing is the formulation of medical insurance payment price "There's no problem in liberalizing drug price control, but it's impossible for drug companies to sell as much as they want, and the national finance can't afford to pay for medical insurance, which is the difficulty." The official said the drug bidding system will not disappear in the short term How to bypass the bidding price, so that pharmaceutical companies can really price freely according to the market supply and demand? The plan given by Liao Xinbo is, "who pays for the bidding? Since it is medical insurance that pays for the bidding, the medical insurance department is responsible for the bidding On the premise that the total amount of medical insurance payment is determined, each drug shall be priced in the market " "At present, our drug bidding is not a real market bidding." Liao Xinbo said, "if it is a real market bidding, it is to choose the most appropriate medicine among many varieties, that is, to focus on the best cost-effective effect and price, rather than the cheapest We always emphasize the price now, either dead in one move or higher in the more moves " Liao Xinbo said that the government does not supply or consume drugs, so it seems strange that the government is responsible for unified bidding The government should not bid for drugs as the main body, but directly by the medical insurance department, which provides drugs to the insured according to the doctor's prescription "The medical insurance department is responsible for bidding, which can not only bypass the restrictions of local bidding price, make the market play a pricing role, but also avoid the soaring drug price after the drug price is released."